Differential effect of schisandrin b stereoisomers on ATR-mediated DNA damage checkpoint signaling

Journal of Pharmacological Sciences

Volumn 122, Issue 2, 2013, Pages 138-148

  Tatewaki, Naoto ^a,b   Nishida, Hiroshi ^a   Yoshida, Masaaki ^c   Ando, Hidehiro ^c   Kondo, Seizo ^c   Sakamaki, Toshiyuki ^b   Konishi, Tetsuya ^a  

^a Faculty of Applied Life Sciences   (Japan)

^b NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^c Kotaro Pharmaceutical Co Ltd   (Japan)

Author keywords

Ataxia telangiectasia and Rad 3 related (ATR); Checkpoint; DNA damage; Gomisin N; Schisandrin B

Indexed keywords

ATR PROTEIN; CHECKPOINT KINASE 1; GOMISIN; PROTEIN P53; SCHIZANDRIN B; SCHIZANDRIN C; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ARTICLE; CELL DEATH; CELL LINE; CELL STRAIN A549; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIASTEREOISOMER; DNA DAMAGE CHECKPOINT; DRUG EFFECT; ENZYME ACTIVITY; ENZYME PURIFICATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEREOISOMERISM; STEREOSPECIFICITY; ULTRAVIOLET RADIATION;

EID: 84880851265     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13048FP     Document Type: Article

References (50)

1. Friedberg EC, McDaniel LD, Schultz RA. The role of endogenous and exogenous DNA damage and mutagenesis. Curr Opin Genet Dev. 2004;14:5-10.
2. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28:739-745.
3. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev. 2001;11:71-77.
4. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3:155-168.
5. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001;15:2177-2196.
6. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23:2825-2837.
7. Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007;67:339-345
8. On KF, Chen Y, Ma HT, Chow JP, Poon RY. Determinants of mitotic catastrophe on abrogation of the G2 DNA damage checkpoint by UCN-01. Mol Cancer Ther. 2011;10:784-794.
9. Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today. 2012; 17:194-202.
10. Nishida H, Tatewaki N, Nakajima Y, Magara T, Ko KM, Hamamori Y, et al. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res. 2009;37:5678-5689.
11. Liu GT. Pharmacological actions and clinical use of fructus schizandrae. Chin Med J. 1989;102:740-749.
12. Li X Y. Bioactivity of neolignans from fructus Schizandrae. Mem Inst Oswaldo Cruz. 1991;86:31-37.
13. Nishida H, Kushida M, Nakajima Y, Ogawa Y, Tatewaki N, Sato S, et al. Amyloid-beta-induced cytotoxicity of PC-12 cell was attenuated by Shengmai-san through redox regulation and outgrowth induction. J Pharmacol Sci. 2007;104:73-81.
14. Harper JV. Synchronization of cell populations in G1/S and G2/M phases of the cell cycle. Methods Mol Biol. 2005;296: 157-166.
15. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 1999;59:4375-4382.
16. Durocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?. Curr Opin Cell Biol. 2001;13:225-231.
17. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179-204.
18. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9:616-627.
19. Wagner JM, Kaufmann SH. Prospects for the use of ATR inhibitors to treat cancer. Pharmaceuticals. 2010;3:1311-1334.
20. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting expression of ataxia-telangiec-tasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet. 2003;33:497-501.
21. Motoyama N, Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev. 2004;14:11-16.
22. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 2000; 14:397-402.
23. De Klein A, Muijtjens M, van Os R, Verhoeven Y, Smit B, Carr AM, et al. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol. 2000;10:479-482.
24. Gilad S, Khosravi R, Shkedy D, Uziel T, Ziv Y, Savitsky K, et al. Predominance of null mutations in ataxia-telangiectasia. Hum Mol Genet. 1996;5:433-439.
25. Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996;86:159-171.
26. Khanna KK, Lavin MF, Jackson SP, Mulhern TD. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ. 2001;8:1052-1065.
27. Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, et al. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res. 1998; 18:657-666.
28. Tsuchiya H, Yamamoto N, Asada N, Terasaki T, Kanazawa Y, Takanaka T, et al. Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma. Anticancer Res. 2000;20:2137-2143.
29. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, et al. Caffeine-potentiated chemotherapy for meta-static carcinoma and lymphoma of bone and soft tissue. Anti-cancer Res. 2005;25:2399-2405.
30. Takeuchi A, Tsuchiya H, Yamamoto N, Hayashi K, Yamauchi K, Kawahara M, et al. Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res. 2007;27:3489-3495.
31. Kimura H, Tsuchiya H, Shirai T, Nishida H, Hayashi K, Takeuchi A, et al. Caffeine-potentiated chemotherapy for metastatic osteosarcoma. J Orthop Sci. 2009;14:556-565.
32. Bhilwade HN, Tatewaki N, Giridharan VV, Nishida H, Konishi T. Modulation of doxorubicin-induced genotoxicity by squalene in Balb/c mice. Food Funct. 2010;1:174-179.
33. Tatewaki N, Bhilwade HN, Nishida H, Nakajima Y, Konishi T. Manipulation of DNA damage checkpoint signaling in cancer cells by antioxidant biofactor (AOB). Food Funct. 2013;4: 63-73.
34. Luk KF, Ko KM, Ng KM. Separation and Purification of Schisandrin B from Fructus Schisandrae. Ind Eng Chem Res. 2008;47:4193-4201.
35. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
36. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14:3-15.
37. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
38. Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P, et al. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat. 2002;19:149-164.
39. Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem. 2011;54:2320-2330.
40. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011; 7:428-430.
41. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol. 2011;18:721-727.
42. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996; 88:956-965.
43. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem. 2000;275:5600-5605.
44. Tse AN, Schwartz GK. Potentiation of cytotoxicity of topoisom-erase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 2004;64:6635-6644.
45. Slaninová I, Brezinová L, Koubíková L, Slanina J. Dibenzo-cyclooctadiene lignans overcome drug resistance in lung cancer cells-study of structure-activity relationship. Toxicol In Vitro. 2009;23:1047-1054.
46. Yim SY, Lee YJ, Lee YK, Jung SE, Kim JH, Kim HJ, et al. Gomisin N isolated from Schisandra chinensis significantly induces anti-proliferative and pro-apoptotic effects in hepatic carcinoma. Mol Med Report. 2009;2:725-732.
47. Gnabre J, Unlu I, Chang TC, Lisseck P, Bourne B, Scolnik R, et al. Isolation of lignans from Schisandra chinensis with anti-proliferative activity in human colorectal carcinoma: structure-activity relationships. J Chromatogr B. Analyt Technol Biomed Life Sci. 2010;878:2693-2700.
48. Oh SY, Kim YH, Bae DS, Um BH, Pan CH, Kim CY, et al. Anti-inflammatory effects of gomisin N, gomisin J, and schisan-drin C isolated from the fruit of Schisandra chinensis. Biosci Biotechnol Biochem. 2010;74:285-291.
49. Chae HS, Kang OH, Oh YC, Choi JG, Keum JH, Kim SB, et al. Gomisin N has anti-allergic effect and inhibits inflammatory cytokine expression in mouse bone marrow-derived mast cells. Immunopharmacol Immunotoxicol. 2011;33:709-713.
50. Lam P Y, Ko KM. (-)Schisandrin B ameliorates paraquat-induced oxidative stress by suppressing glutathione depletion and enhancing glutathione recovery in differentiated PC12 cells. Biofactors. 2011;37:51-57.